Equity

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss

Vertex Pharmaceuticals AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss decreased by 15.2% to $8.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.5%, from $7.60M to $8.40M.

Analysis

StatementBalance Sheet Statement
SectionEquity
First reportedQ1 2023
Last reportedQ1 2026May 5, 2026
Metric ID: afs_debt_securities_unrealized_loss_12m_plus_acc

Historical Data

10 periods
 Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$0.00$0.00$0.00$400.00K$382.40M$68.60M$7.60M$6.20M$9.90M$8.40M
QoQ Change————>999%-82.1%-88.9%-18.4%+59.7%-15.2%
YoY Change——————>999%-98.4%-85.6%+10.5%
Range$0.00 – $382.40M
Avg YoY Growth+406.6%
Median YoY Growth-37.5%

Frequently Asked Questions

What is Vertex Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months) accumulated loss?
Vertex Pharmaceuticals (VRTX) reported afs and trading securities - unrealized loss position (>=12 months) accumulated loss of $8.40M in Q1 2026.
How has Vertex Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months) accumulated loss changed year-over-year?
Vertex Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months) accumulated loss increased by 10.5% year-over-year, from $7.60M to $8.40M.